These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21804067)

  • 1. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.
    Meriwether D; Imaizumi S; Grijalva V; Hough G; Vakili L; Anantharamaiah GM; Farias-Eisner R; Navab M; Fogelman AM; Reddy ST; Shechter I
    J Lipid Res; 2011 Oct; 52(10):1795-809. PubMed ID: 21804067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.
    Wool GD; Vaisar T; Reardon CA; Getz GS
    J Lipid Res; 2009 Sep; 50(9):1889-900. PubMed ID: 19433476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.
    Navab M; Reddy ST; Van Lenten BJ; Buga GM; Hough G; Wagner AC; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2553-60. PubMed ID: 23077141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
    Wool GD; Reardon CA; Getz GS
    J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of HDL mimetic peptide 4F on PON1.
    Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
    Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.
    Imaizumi S; Grijalva V; Navab M; Van Lenten BJ; Wagner AC; Anantharamiah GM; Fogelman AM; Reddy ST
    Drug Metab Lett; 2010 Aug; 4(3):139-48. PubMed ID: 20642447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
    Ou J; Wang J; Xu H; Ou Z; Sorci-Thomas MG; Jones DW; Signorino P; Densmore JC; Kaul S; Oldham KT; Pritchard KA
    Circ Res; 2005 Nov; 97(11):1190-7. PubMed ID: 16224061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.
    Vaziri ND; Moradi H; Pahl MV; Fogelman AM; Navab M
    Kidney Int; 2009 Aug; 76(4):437-44. PubMed ID: 19471321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
    Sherman CB; Peterson SJ; Frishman WH
    Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
    Navab M; Ruchala P; Waring AJ; Lehrer RI; Hama S; Hough G; Palgunachari MN; Anantharamaiah GM; Fogelman AM
    J Lipid Res; 2009 Aug; 50(8):1538-47. PubMed ID: 19225094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic inflammation, intestine, and paraoxonase-1.
    Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
    Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.
    Buga GM; Navab M; Imaizumi S; Reddy ST; Yekta B; Hough G; Chanslor S; Anantharamaiah GM; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):283-9. PubMed ID: 19965777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway.
    Liu D; Ding Z; Wu M; Xu W; Qian M; Du Q; Zhang L; Cui Y; Zheng J; Chang H; Huang C; Lin D; Wang Y
    J Mol Cell Cardiol; 2017 Apr; 105():77-88. PubMed ID: 28274624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
    Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
    J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.
    Nayyar G; Mishra VK; Handattu SP; Palgunachari MN; Shin R; McPherson DT; Deivanayagam CCS; Garber DW; Segrest JP; Anantharamaiah GM
    J Lipid Res; 2012 May; 53(5):849-858. PubMed ID: 22377531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide.
    Van Lenten BJ; Wagner AC; Anantharamaiah GM; Garber DW; Fishbein MC; Adhikary L; Nayak DP; Hama S; Navab M; Fogelman AM
    Circulation; 2002 Aug; 106(9):1127-32. PubMed ID: 12196340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
    Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM
    Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.